Source: Annual Congress 2005 - COPD - treatment III
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Mason, J. Sparrow, R. M. Angus (Liverpool, United Kingdom). Corticosteroid and long acting beta agonist combination inhalers in COPD: the right device for the right patient?. Eur Respir J 2005; 26: Suppl. 49, 1953

Member's Comments

No comment yet.

Related content which might interest you: Are we selecting the right inhaler for the right COPD patient? Source: Virtual Congress 2021 – Part I: restarting COPD care in the post-COVID era Year: 2021 Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 What predicts short-acting beta agonist (SABA) monotherapy use in children? Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Inhaled medication: which device for which patient? Source: Eur Respir Monogr 2015; 69: 213-223 Year: 2015 Getting it right: What does inhaler choice mean for patient outcomes? Source: International Congress 2019 – Putting COPD patient needs first: Time for optimizing treatment and device selection Year: 2019 Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Triple therapy in COPD: only for the right patient Source: Eur Respir J, 53 (4) 1900394; 10.1183/13993003.00394-2019 Year: 2019 Combined inhaled corticosteroid and long acting β agonist treatment of paediatric asthma: experience of an asthma care programme Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Is there a problem with short-acting beta-2 agonist monotherapy in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020 First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Combination of inhaled corticosteroids and long acting beta two agonists improve lung clearance index (LCI) in preschoolers with cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Efficacy of an inhaled corticosteroid/long-acting ?2-agonist combination in symptomatic COPD patients in GOLD groups B and D Source: Eur Respir J 2015; 46: 255-258 Year: 2015 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014